Douglas J. Rhee, MD

B. SYSTEMICNote: All have significant side effects that need to be monitored (refer to insert below).Drug Trade Dose Notesacyclovir Zovirax 400 mg PO BID indefinitely For prevention of recurrent HSV keratitis400 mg PO 3–5×/day for 7–10 days For HSV keratitis/dermatitis800 mg PO 5× day for 7–10 days For VZV ophthalmicus (if within 72 hours of rash onset)5 mg/kg IV Q8 hr × 7–10 days For HSV in immunocompromised patient; adjust dose inrenal failure 110 mg/kg IV Q8 hr × 7–14 days For primary/disseminated VZV; adjust dose in renal failure 11500 mg/m 2 /day IV in 3 divided doses × For acute retinal necrosis 2 ; should consider chronic oral7–10 days suppressive dose; adjust dose in renal failure 1cidofovir Vistide 5 mg/kg IV Qweek for 2 weeks then For CMV retinitis in HIV + patients; hydration and3–5 mg/kg Q2 weeks probenicid 3 must be given with both intravit and IV;adjust dose in renal failure 1 ; renal function with serumcreatinine and urine protein must be monitored within 48hours before each dose and dose modified granulocytopenia—monitor neutrophil counts contraindicated if serumcreatinine >1.5 mg/dl, creat clearance 100 mg/dlfamciclovir Famvir 500 mg PO TID × 7 days For VZV ophthalmicus (if within 72 hours of rash onset);must adjust dose in renal failure 1250–500 mg PO BID indefinitely For prevention of recurrent HSV keratitis(continued)Antiviral Agents 43